ABSTRACT
Objective To examine how and when the results of COVID-19 clinical trials are disseminated.
Design Cross-sectional bibliographic study
Setting The COVID-19 clinical trial landscape
Participants 285 registered interventional clinical trials for the treatment and prevention of COVID-19 completed by 30 June 2020
Main outcome measures Overall reporting and reporting by dissemination route (i.e., by journal article, preprint, or results on a registry); time to reporting by dissemination route.
Results Following automated and manual searches of the COVID-19 literature, we located 41 trials (14%) with results spread across 47 individual results publications published by 15 August 2020. The most common dissemination route was preprints (n = 25) followed by journal articles (n = 18), and results on a registry (n = 2). Of these, four trials were available as both a preprint and journal publication. The cumulative incidence of any reporting surpassed 20% at 119 days from completion. Sensitivity analyses using alternate dates available and definitions of results did not appreciably change the reporting percentage. Expanding minimum follow-up time to 3 months increased the overall reporting percentage to 19%.
Conclusion COVID-19 trials completed during the first six months of the pandemic did not consistently yield rapid results in the literature or on clinical trial registries. Our findings suggest that the COVID-19 response may be seeing quicker results disclosure compared to non-emergency conditions. Issues with the reliability and timeliness of trial registration data may impact our estimates. Ensuring registry data is accurate should be a priority for the research community during a pandemic. Data collection is underway for Phase 2 of the DIRECCT study expanding our trial population to those completed anytime in 2020.
Competing Interest Statement
All authors declare that they have no direct conflict of interest related to this work. Outside of the submitted work, NJD has received a doctoral studentship from the Naji Foundation, grant support from the Fetzer-Franklin Memorial Fund, and been employed on a grant from the Laura and John Arnold Foundation. MSH is employed as a researcher under additional grants from the German Bundesministerium für Bildung und Forschung (BMBF). PG received grant funding from the BMBF and Mercator Foundation and consults for scite inc. MPJ received grant funding from the BMBF. DS serves as a member of the Sanofi Advisory Bioethics Committee and receives an honorarium for contributing to meetings.
Clinical Trial
This study was preregistered on the OSF: https://osf.io/8fr9t
Funding Statement
The CEOsys project is funded under a scheme issued by the Network of University Medicine (Nationales Forschungsnetzwerk der Universitätsmedizin - NUM) by the Federal Ministry of Education and Research of Germany (Bundesministerium für Bildung und Forschung - BMBF). FKZ: 01KX2021. During the course of this project NJD was also employed on a grant from The Good Thinking Society to work on trials transparency research. The funders had no involvement in the study design, analysis, or writing of the manuscript nor the decision to submit.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was exempted from ethics approval at the University of Oxford as it solely used non-disclosive, publicly available data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All code for this project is available at https://github.com/ebmdatalab/covid19_results_reporting and https://github.com/maia-sh/direcct. The full dataset is available at https://www.doi.org/10.5281/zenodo.4669937.
https://github.com/ebmdatalab/covid19_results_reporting
